

June 18, 2007
Announcement no. 19

Prospectus announcement

The prospectus for the new issue by BioPorto A/S (hereinafter referred to as “BioPorto” or “the Company”) to take place June 26, 2007, will be published on June 19, 2007.

BioPorto is issuing new shares in a direct placement as mentioned in the 2006 Annual Report, and also in the stock exchange announcements No. 21, of November 6, 2006, and No. 13, of March 19, 2007. As previously announced, both issues are fully subscribed.

The Company will be performing an additional new issue, equal to shares of DKK 5,928,618 nominal value, for converting bonds, cf. Stock Exchange Announcement no. 10, of July 13, 2006, and also with reference to the decision by the Board of Directors to increase the capital as of today’s date, in the following.

The first day of trading will be June 26, 2007, where 13,861,933 class-B shares will be issued at a nominal value of DKK 3.00 per share. As a result of this, the total nominal value of the Company’s capital stock will be DKK 114,644,352, equivalent to 38,214,784 shares at a nominal value of DKK 3.00 per share. The new issue is equivalent to an increase of 56.92%.

The shares are issued under ISIN code DK0011048619.

A prospectus has been prepared as part of the issue process and will be published, via the Company News Service over OMX The Nordic Exchange, Copenhagen, tomorrow, i.e. June 19, 2007. It will be possible to obtain a copy of the prospectus on OMX’s website: www.omxgroup.com, or at the Company’s website: www.bioporto.com. It is also possible to obtain a printed copy of the prospectus by contacting BioPorto A/S, tel. +45 4529 0029, or Korral Partners A/S, tel. +45 3966 6666.

About BioPorto A/S

BioPorto was founded in 2000, with its point of departure being the rights to a large portfolio of developed monoclonal antibodies acquired from Statens Serum Institut. Since then, the Company has further developed the portfolio and today has more than 300 different antibodies on offer, which are sold via distributors. BioPorto has also developed so-called ELISA test kits for selected antibodies for use in research and diagnostics. The intellectual property rights for the use of NGAL as an early kidney marker, have proven to have far greater potential than originally presumed. This gave the Company an important cause for revising its strategy in early 2007.

According to the new strategy, BioPorto must continue to grow by means of development, licensing and acquisitions, if relevant, to increase the number of monoclonal antibodies and antibody-based products that are marketed to the basic research market. By keeping close tabs on this market’s demand, the Company will select monoclonal antibodies that prove to be clinically relevant, can be protected by intellectual property rights and have potential as a new routine test. An ELISA kit will be developed for these selected antibodies, which will make the testing procedure less cost-intensive for clinical research. On the basis of research results,

the Company will also be able to identify whether a new potential marker has clinical potential for being implemented in routine diagnostics.

As the protection of IP rights is a crucial aspect of BioPorto's business model, the Company is proactively seeking to ensure ongoing maintenance and follow-up in this field.

BioPorto's goal is to acquire a share of the routine diagnostics market, which must occur by concluding licensing agreements with major diagnostic companies and by establishing a niche market for the Company's own CE-marked ELISA kits.

Capital increases

The Company is performing two capital increases by means of a direct placement.

First issue:

On August 14, 2006, the Board of Directors for BioPorto A/S decided to make partial use of its mandate from the ordinary general meeting, cf. article 15a of the corporate bylaws, to perform a direct placement of the Company's class-B shares for a limited number of stockholders. The implementation of the issue was conclusively adopted by the Board of Directors, as announced in Stock Exchange Announcement no. 21 of November 6, 2006.

- From August 14–28, 2006, 4,629,625 new class-B shares were subscribed, at a nominal value of DKK 3.00 per share, equivalent to a nominal value of DKK 13,888,875. The initial offering price is set at DKK 4.32 per share, with a nominal value of DKK 3.00 per share. The price is based on the average "price of all transactions" on OMX The Nordic Exchange, Copenhagen, from August 4, 2006, up to and including August 11, 2006.

Second issue:

On March 7, 2007, the Board of Directors for BioPorto A/S decided to make partial use of its mandate from the ordinary general meeting, cf. article 15a of the corporate bylaws, to perform one more direct placement of the Company's class-B shares for a limited number of stockholders. The implementation of the issue was conclusively adopted by the Board of Directors, as announced in Stock Exchange Announcement no. 21 of March 19, 2007.

- From March 9–23, 2007, 5,692,600 new class-B shares were subscribed, at a nominal value of DKK 3.00 per share, equivalent to a nominal value of DKK 17,077,800. The initial offering price is set at DKK 5.27 per share, with a nominal value of DKK 3.00 per share. The price is based on the average "price of all transactions" on OMX The Nordic Exchange, Copenhagen, from March 2, 2007, up to and including March 8, 2007.

The Company will perform an additional new issue for converting bonds.

The Board of Directors decided to issue new shares for conversion insofar as 23 bonds are concerned, on July 12, 2006, cf. Stock Exchange Announcement no. 10, of July 13, 2006.

- The exercise price is DKK 3.50 per share, so that one bond with a nominal value of DKK 250,000 can in its entirety be exchanged for a total of 71,429 shares in the Company, insofar as 18 bonds are concerned, and DKK 4.50 per share, so that one bond with a nominal value of DKK 250,000 can in its entirety be exchanged for a total of 55,556 shares in the Company, insofar as 5 bonds are concerned.

The Board of Directors has also received statements from the remaining holders of convertible bonds (except for one bond-holder who has two bonds), who indicate that they wish to convert their convertible bonds, totaling DKK 8.75 million spread over 35 bonds worth DKK 250,000 each, into common stock at the next opportunity, cf. the provisions of the bond.

As of today's date, the Board of Directors has adopted the capital increase, and the following terms apply to the conversion:

- The Company must take steps to ensure that the shares are issued and listed on the OMX The Nordic Exchange, Copenhagen, as soon as possible after exercising the conversion, which is expected to occur on June 26, 2007.
- The exercise price is DKK 3.50 per share, so that a bond at a nominal value of DKK 250,000 can in its entirety be exchanged for a total of 71,429 shares in the Company, insofar as 2 bonds are concerned, and DKK 4.50 per share, so that a bond at a nominal value of DKK 250,000 can in its entirety be exchanged for a total of 55,556 shares in the Company, insofar as 33 bonds are concerned.
- The payment of interest on the bond will cease from the time of conversion.
- The conversion of the bond will be carried out without a pre-emptive right for the Company's previous stockholders;
- By means of the conversion, the new shares will receive the same rights in the Company as the previous shares.

The capital stock will be increased by the nominal value of DKK 5,928,618 by means of converting an additional 35 bonds. BioPorto will arrange for the issuance and listing of the shares on the Copenhagen Stock Exchange as soon as possible.

The number of shares to be issued on the basis of the conversion of 58 bonds thus total 3,539,708, equivalent to a nominal value of DKK 10,619,124 common stock.

Investors

Investors, cash issue 1

The investors comprise six major banks that are not associated with the Company.

Investors, Issue 1
UBS Luxembourg SA
Handelsbanken A/S
Forstædernes Bank A/S
Sparekassen Kronjylland A/S
Landsbanki Luxembourg SA
Sydbank A/S

Investors, cash issue 2

The Company's previous CFO, Frank Harder, has subscribed to 94,877 shares, while the following major stockholders, without affiliation with the company, have subscribed to more than 5% of the shares issued in the second direct placement:

Investors, Issue 2
Fundamental Fondsbørsselskab A/S
UBS Luxembourg SA
Nykredit Markets A/S
Landsbanki Luxembourg SA
Erik Damgaard Porteføjlinvest A/S
Sparekassen Kronjylland A/S
Forstædernes Bank A/S

Dispersion of new and existing shares

Date	Transaction	No. of class-A shares	No. of class-B shares	Nominal value per share (DKK)	Issue price (DKK)	Nominal value of capital increases (DKK)	Total no. of shares	Total capital stock (nom. DKK)
Status June 8, 2007	Existing outstanding shares	20,000	24,332,851	3.00		73,058,553	24,352,851	73,058,553
prospectus date	Direct placement, cash subscription		4,629,625	3.00	4.32	13,888,875	28,982,476	86,947,428
prospectus date	Direct placement, cash subscription		5,692,600	3.00	5.27	17,077,800	34,675,076	104,025,228
prospectus date	Conversion of bonds		1,428,580	3.00	3.50	4,285,740	36,103,656	108,310,968
prospectus date	Conversion of bonds		2,111,128	3.00	4.50	6,333,384	38,214,784	114,644,352

Application of proceeds

The Company has received gross proceeds of DKK 50 million from the capital increase.

The proceeds will be used to strengthen BioPorto's financial base in the negotiations relating to licensing access to the NGAL patent. In addition, the proceeds will partly be used for supporting the expansion of the company's new product portfolio (both for intensifying current ongoing development activities and for licensing new products), but primarily for implementing a significant intensification of the Company's sales and marketing activities.

Schedule

Announcement of a prospectus announcement: June 18, 2007

Announcement of a prospectus via Company News Service: June 19, 2007

First day of trading for the new shares: June 26, 2007



Additional information:

Please contact Thea Olesen, Managing Director.

BioPorto A/S
Grusbakken 8
DK-2820 Gentofte
www.bioporto.com

Tel.: +45 4529 0029
E-mail: info@bioporto.com

The Company's financial advisor in connection with the capital increase

Korral Partners A/S
Kongens Nytorv 26, 4th floor
DK-1050 Copenhagen K

Tel.: +45 3966 6666
Fax: +45 3966 6600